4-Aminopyridine derivatives with anticholinesterase and antiamnesic activity

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 1, 2008, Pages 309-312

  Scipione, Luigi ^a   De Vita, Daniela ^a   Musella, Alessandra ^a   Flammini, Lisa ^b   Bertoni, Simona ^b   Barocelli, Elisabetta ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

4 Aminopyridine derivatives; Acetylcholinesterase; Antiamnesic effects; Butyrylcholinesterase

Indexed keywords

4 AMINOPYRIDINE DERIVATIVE; CARBAMIC ACID DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; SCOPOLAMINE;

AMNESIA; ARTICLE; CHOLINESTERASE INHIBITION; DRUG ACTIVITY; DRUG INDICATION; DRUG SYNTHESIS; NONHUMAN; PASSIVE AVOIDANCE;

4-AMINOPYRIDINE; AMNESIA; ANIMALS; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; CARBAMATES; CHOLINESTERASE INHIBITORS; KINETICS; RATS; SCOPOLAMINE;

RATTUS;

EID: 37549036692     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.10.077     Document Type: Article

References (24)

1. Bartus R.T., Dean III R.L., Beer B., and Lippa A.S. Science 217 (1982) 408
2. Whitehouse P.J., Price D.L., and Struble R.G. Science 215 (1982) 1237
3. Perry E.K., Perry R.H., Blessed G., and Tomlinson B.E. Neuropath. Appl. Neuro. 4 (1978) 273
4. Gil-Bea F.J., Garcia-Alloza M., Dominguez J., Marcos B., and Ramirez M.J. Neurosci. Lett. 375 (2005) 37
5. Mohs R.C., Doody R.S., Morris J.C., Ieni J.R., Rogers S.L., Perdomo C.A., and Pratt R.D. Neurology 57 (2001) 481
6. Olin, J.; Schneider, L. Cochrane database of systematic reviews 2001, 4, CD001747.
7. Birks, J. Cochrane Database of Systematic Reviews 2006, 1, CD005593.
8. Carelli, V.; Liberatore, F.; Scipione, L.; Rotiroti, D.; Rispoli, V.; Cardellini M, Patent IT MI 2000 A000898 (2000), EP 1925883.(2001).
9. Carelli V., Liberatore F., Scipione L., Rotiroti D., Rispoli V., and Cardellini M. Chem. Abst. 135 (2001) 344212m
10. Rispoli V., Rotiroti D., Carelli V., Liberatore F., Scipione L., Marra R., Giorgioni G., and Di Stefano A. Neurosci. Lett. 356 (2004) 199
11. Rispoli V., Rotiroti D., Carelli V., Liberatore F., Scipione L., Marra R., Tortorella S., and Bi Rienzo B. Pharmacol. Biochem. Behav. 78 (2004) 667
12. Rispoli V., Marra R., Costa N., Scipione L., Rotiroti D., De Vita D., Liberatore F., and Carelli V. Pharmacol. Biochem. Behav. 84 (2006) 453
13. Papke R.L., Bencherif M., and Lippiello P. Neurosci. Lett. 213 (1996) 201
14. Alkondon M., Pereira E.F.R., Cortes W.S., Maelicke A., and Albuquerque E.X. Eur. J. Neurosci. 9 (1997) 2734
15. Breese C.R., Adams C., Logel J., Drebing C., Rollins Y., Barnhart M., Sullivan B., Demasters B.K., Freedman R., and Leonard S. J. Comp. Neurol. 387 3 (1997) 385
16. Davidson M., Zemishlany J.H., and Mohs R.C. Biol. Psychiatry 23 (1988) 485
17. Smith C.P., Bores G.M., Petko W., Li M., Selk D.E., Rush D.K., Camacho F., Winslow J.T., Fishkin R., Cunningham D.M., Brooks K.M., Roehr J., Hartman H.B., Davis L., and Vargas H.M. J. Pharmacol. Exp. Ther. 280 (1997) 710
18. Passive avoidance performance test was carried out according to the step-through method described by Giovannini (Behaviour Brain Research 1999, 104: 147-155). The time elapsed between the rat was placed in the light and it entered the dark compartment is recorded as Training Trial latency time (TT). Amnesia was induced in rats with scopolamine (0.5 mg/kg) given subcutaneously 1 h before Training Trial. Rats received intraperitoneally the compounds under study (4-AP, 3a, 4a, 4d) or vehicle (saline) 30 min after scopolamine treatment. Compound 1 was given 15 min before Training Trial. In a second set of experiments 1 was combined with 4-AP following the same experimental protocol. Retention trial was performed 24 h later, following a similar procedure, except that the electric shock was not given. The latency time to enter the dark compartment was measured up to a cut off time of 180 s and indicated as Retention Trial latency time (RT). Experiments were done in compliance with the recommendations of the EEC 886/609/CEE and in accordance with the national laws (DL 116/92).
19. Youdim M.B.H., and Buccafusco J.J. J. Neural. Transm. 112 (2005) 519
20. 13C NMR and analytical data are reported in supplementary material.
21. Ellman G.L., Courtney K.D., Andres V., and Featherstone R.M. Biochem. Pharmacol. 7 (1961) 88
22. Dixon M. Biochem. J. 55 (1953) 170
23. Recanatini M., Cavalli A., Belluti F., Piazzi L., Rampa A., Bisi A., Gobbi S., Valenti P., Andrisano V., Bartolini M., and Cavrini V. J. Med. Chem. 43 (2000) 2007
24. Bartolini M., Bertucci C., Cavrini V., and Andrisano V. Biochem. Pharmacol. 65 (2003) 407